Valuation: Evotec SE

Market Cap 46Cr 52Cr 43Cr 39Cr 74Cr 4.92TCr 74Cr 518.31Cr 202.57Cr 2.56TCr 194.12Cr 189.87Cr 8.19TCr P/E 2026 *
-2.04x
P/E 2027 * -6.06x
Enterprise Value 61Cr 68Cr 56Cr 51Cr 96Cr 6.44TCr 97Cr 678.02Cr 264.99Cr 3.34TCr 253.93Cr 248.38Cr 11TCr EV / Sales 2026 *
1.01x
EV / Sales 2027 * 0.87x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+6.71%
1 week-11.23%
Current month-15.87%
1 month-12.13%
3 months-47.23%
6 months-44.51%
Current year-52.15%
1 week 2.41
Extreme 2.406
2.93
1 month 2.41
Extreme 2.406
3.14
Current year 2.41
Extreme 2.406
6.73
1 year 2.41
Extreme 2.406
7.3
3 years 2.41
Extreme 2.406
21.69
5 years 2.41
Extreme 2.406
45.47
10 years 2.41
Extreme 2.406
45.83
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/26 Exercice

Chief Technology Officer

12,462 0.0070%
04/05/26 Buy 15,510 0.0087%
04/05/26 Buy

Head of Human Resources

15,228 0.0086%
Change 5-day change 1-year change 3-year change Capi.($)
+6.71%-11.23%-61.57%-84.71% 49Cr
-2.01%-7.86%+54.60%+70.97% 7.04TCr
+3.84%-10.61%+6.97%+57.43% 5.03TCr
+3.35%+1.60%+10.58%+40.01% 4.75TCr
+0.51%+0.78%+28.58%+31.43% 4.29TCr
+2.70%-3.18%+296.96%+547.01% 4.04TCr
+0.69%-3.11%+7.48%+96.59% 3.97TCr
+0.06%-1.43%+10.47%+43.27% 3.06TCr
-2.95%-14.09%+37.94%+1.30% 2.68TCr
-0.39%-7.39%-13.33%-14.40% 2.24TCr
Average +1.25%-6.70%+37.87%+78.89% 3.71TCr
Weighted average by Cap. +0.77%-5.45%+51.75%+102.45%

Financials

2026 *2027 *
Net sales 60Cr 67Cr 56Cr 51Cr 95Cr 6.36TCr 96Cr 669.53Cr 261.67Cr 3.3TCr 250.75Cr 245.27Cr 11TCr 72Cr 81Cr 67Cr 61Cr 114.59Cr 7.66TCr 115.49Cr 806.57Cr 315.23Cr 3.98TCr 302.08Cr 295.48Cr 13TCr
Net income -22Cr -25Cr -21Cr -19Cr -35Cr -2.36TCr -36Cr -248.2Cr -97Cr -1.22TCr -93Cr -91Cr -3.92TCr -4.83Cr -5.39Cr -4.49Cr -4.08Cr -7.66Cr -512.18Cr -7.72Cr -54Cr -21Cr -266.02Cr -20Cr -20Cr -852.19Cr
Net Debt 14Cr 16Cr 13Cr 12Cr 23Cr 1.52TCr 23Cr 159.72Cr 62Cr 787.59Cr 60Cr 59Cr 2.52TCr 16Cr 18Cr 15Cr 14Cr 26Cr 1.72TCr 26Cr 181.31Cr 71Cr 894.09Cr 68Cr 66Cr 2.86TCr
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
14/26/14 €2.608 +6.71% 23,56,377
13/26/13 €2.444 -0.65% 16,17,177
12/26/12 €2.460 -11.13% 42,51,059
09/26/09 €2.768 -1.35% 7,82,994
08/26/08 €2.806 -4.36% 11,81,049
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.608EUR
Average target price
4.443EUR
Spread / Average Target
+70.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE